Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 85% Improvement Relative Risk ICU admission 95% Vitamin D for COVID-19  Jain et al.  Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Prospective study of 154 patients in India Lower mortality (p=0.0014) and ICU admission (p<0.0001) c19early.org Jain et al., Nature, November 2020 Favors vitamin D Favors control

Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers

Jain et al., Nature, doi:10.1038/s41598-020-77093-z
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 119 studies, recognized in 7 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Prospective study of 91 asymptomatic and 63 ICU patients showing significantly higher vitamin D deficiency in the ICU patients (97% vs. 33%).
This is the 28th of 192 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 611 vigintillion).
risk of death, 85.2% lower, RR 0.15, p = 0.001, high D levels 2 of 64 (3.1%), low D levels 19 of 90 (21.1%), NNT 5.6, >20ng/mL.
risk of ICU admission, 95.4% lower, RR 0.05, p < 0.001, high D levels 2 of 64 (3.1%), low D levels 61 of 90 (67.8%), NNT 1.5, >20ng/mL.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jain et al., 19 Nov 2020, prospective, India, peer-reviewed, 6 authors.
This PaperVitamin DAll
Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers
Anshul Jain, Rachna Chaurasia, Narendra Singh Sengar, Mayank Singh, Sachin Mahor, Sumit Narain
Scientific Reports, doi:10.1038/s41598-020-77093-z
COVID-19 is characterized by marked variability in clinical severity. Vitamin D had recently been reviewed as one of the factors that may affect the severity in COVID-19. The objective of current study is to analyze the vitamin D level in COVID-19 patients and its impact on the disease severity. After approval from Ethics Committee, M.L.B Medical College the current study was undertaken as continuous prospective observational study of 6 weeks. Participants were COVID-19 patients of age group 30-60 years admitted during the study period of 6 weeks. Study included either asymptomatic COVID-19 patients (Group A) or severely ill patients requiring ICU admission (Group B). Serum concentration of 25 (OH)D, were measured along with serum IL-6; TNFα and serum ferritin. Standard statistical analysis was performed to analyze the differences. Current Study enrolled 154 patients, 91 in Group A and 63 patients in Group B. The mean level of vitamin D (in ng/mL) was 27.89 ± 6.21 in Group A and 14.35 ± 5.79 in Group B, the difference was highly significant. The prevalence of vitamin D deficiency was 32.96% and 96.82% respectively in Group A and Group B. Out of total 154 patients, 90 patients were found to be deficient in vitamin D (Group A: 29; Group B: 61). Serum level of inflammatory markers was found to be higher in vitamin D deficient COVID-19 patients viz. IL-6 level (in pg/mL) 19.34 ± 6.17 vs 12.18 ± 4.29; Serum ferritin 319.17 ± 38.21 ng/mL vs 186.83 ± 20.18 ng/ mL; TNFα level (in pg/mL) 13.26 ± 5.64 vs 11.87 ± 3.15. The fatality rate was high in vitamin D deficient (21% vs 3.1%). Vitamin D level is markedly low in severe COVID-19 patients. Inflammatory response is high in vitamin D deficient COVID-19 patients. This all translates into increased mortality in vitamin D deficient COVID-19 patients. As per the flexible approach in the current COVID-19 pandemic authors recommend mass administration of vitamin D supplements to population at risk for COVID-19. In December 2019, several cases of pneumonia with unknown etiology reported in Wuhan, Hubei Province, China 1,2 . The disease spread quickly to other provinces of China and overseas. On 7 January 2020, a novel coronavirus was identified in the throat swab sample of one such patient and later declared to be the etiologic virus and was subsequently named as 2019nCoV by World Health Organization (WHO) 3 . On worsening of the situation WHO declared the outbreak as the public health emergency of international concern (PHEIC). In February 2020, WHO provided a nomenclature to the epidemic disease caused by SARS-CoV-2 as coronavirus disease 2019 (COVID-19) 4 . As on 12th August 2020 there are more than 20 million cases worldwide 5 , so for now it's almost impossible to contain the disease spread and focus is diverting towards better treatment and prevention of factors that enhance the severity of COVID-19. COVID-19 is characterized by its high infectivity and marked variability in clinical severity, of which..
Author contributions Competing interests The authors declare no competing interests.
References
Aparna, Muthathal, Nongkynrih, Gupta, Vitamin D deficiency in India, J. Family Med. Prim. Care, doi:10.4103/jfmpc.jfmpc_78_18
Argyropoulos, Association of initial viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and symptoms, Am. J. Pathol, doi:10.1016/j.ajpath.2020.07.001
Baeke, Takiishi, Korf, Vitamin D: modulator of the immune system, Curr. Opin. Pharmacol
Biesalski, Vitamin D deficiency and co-morbidities in COVID-19 patients: a fatal relationship?, Nfs J, doi:10.1016/j.nfs.2020.06.001
Bikle, Vitamin D metabolism, mechanism of action, and clinical applications, Chem. Biol, doi:10.1016/j.chembiol.2013.12.016
Cardoso, Pereira, Native vitamin D in pre-dialysis chronic kidney disease, Nefrologia, doi:10.1016/j.nefro.2018.07.004
Cascella, Evaluation and Treatment Coronavirus (COVID-19)
Chen, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, doi:10.1016/S0140-6736(20)30211-7
Ciceri, Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis, Crit. Care Resusc
Gombart, Pierre, Maggini, A review of micronutrients and the immune system-working in harmony to reduce the risk of infection, Nutrients, doi:10.3390/nu12010236
Hill, Mantzoros, Sowers, Commentary: COVID-19 in patients with diabetes, Metabolism, doi:10.1016/j.metabol.2020.154217
Holick, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline [published correction appears in, J Clin Endocrinol Metab
Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Hughes, Norton, Vitamin D and respiratory health, Clin. Exp. Immunol, doi:10.1111/j.1365-2249.2009.04001.x
Hunter, Jones, IL-6 as a keystone cytokine in health and disease, Nat. Immunol
Jones, Jenkins, Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer, Nat. Rev. Immunol, doi:10.1038/s41577-018-0066-7
Kamboj, Dwivedi, Toteja, Prevalence of hypovitaminosis D in India & way forward, Indian J. Med. Res, doi:10.4103/ijmr.IJMR_1807_18
Laird, Rhodes, Kenny, Vitamin D and inflammation: potential implications for severity of covid-19, Ir. Med. J
Latz, Blood type and outcomes in patients with COVID-19, Ann. Hematol, doi:10.1007/s00277-020-04169-1
Magro, SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the "culprit lesion" of ARDS onset? What is there besides Tocilizumab?, Cytokine X, doi:10.1016/j.cytox.2020.100029
Martineau, Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data, BMJ
Nile, COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons, Cytokine Growth Factor Rev, doi:10.1016/j.cytogfr.2020.05.002
Prietl, Treiber, Piber, Amrein, Vitamin D and immune function, Nutrients
Thacher, Clarke, Vitamin D insufficiency, Mayo Clin. Proc, doi:10.4065/mcp.2010.0567
Wacker, Holick, Vitamin D: effects on skeletal and extraskeletal health and the need for supplementation, Nutrients, doi:10.3390/nu5010111
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease, doi:10.1001/jama.2020.2648
Xu, Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system, Mol. Med. Rep, doi:10.3892/mmr.2017.7546
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit